Christie Clinic Vascular Surgeon Featured on Lifetime TV Series


Local vascular surgeon and national chairperson of the LUCY Study: Evaluation of Females Who Are Underrepresented Candidates for Abdominal Aortic Aneurysm Repair (LUCY) will be featured on an upcoming episode of the series, Access Health, on Lifetime TV. The episode is titled, Abdominal Aortic Aneurysms – Understanding Your Options.

  • Jennifer Ash, MD, Christie Clinic Vein & Vascular Center featured on Access Health series, Lifetime TV network
  • Episode: Abdominal Aortic Aneurysms – Understanding Your Options
  • Air dates: February 13th and 20th on Lifetime TV

Abdominal aortic aneurysms (AAA) are often termed the “silent killer,” because they provide no warning signs until they rupture, an event that can lead to death 90% of the time.

Although 21% of AAAs in the United States occur in women, only 6% to 15% of patients enrolled in endovascular AAA investigational device studies are female. Women have traditionally had limited eligibility and worse outcomes after EVAR.

Ash states that, “There is a dichotomy when considering AAAs in women. On one hand, there is evidence to support the idea that when women present with an AAA, they have a faster rate of AAA growth, a higher rupture risk, and a propensity for AAA rupture at smaller diameters. These facts would lead one to believe that perhaps we should be more aggressive in treating women who present with an AAA. On the other hand, we also know that historically, women demonstrate a higher perioperative morbidity and mortality when it comes to AAA repair. Those poor 30-day outcomes have likely curbed our collective enthusiasm for repairing AAAs in women using minimally invasive endograft technologies.”

The LUCY Study is the first prospective trial to assess outcomes of minimally invasive AAA repair in women versus men. The initial results of the LUCY study suggest that women treated with the Ovation System have similar procedural outcomes, no death, no conversion, low 30-day MAE rates, and low rates of endoleaks at 30 days compared with the men in the study. Furthermore, an analysis comparing the outer diameters of several EVAR delivery systems and the maximum diameter of the iliac access vessels of LUCY patients shows that Ovation would expand eligibility for women with AAAs by at least 28%.

“I hope that the study’s results start a dialogue among physicians about aneurysms in women and how we assess and treat them. Perhaps we can look at women with aneurysms in a different light if we can demonstrate both the safety and efficacy of elective AAA repair in this population,” states Ash. “The trial raises the question, which is more tenuous for women with AAA – the disease process and its progress or the treatment itself? Our current thinking is being challenged by the very promising results of this novel trial.”

Dr. Ash discusses the segment on WCIA News.